These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36505840)

  • 1. Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database.
    Barbieri MA; Sorbara EE; Cicala G; Santoro V; Cutroneo PM; Franchina T; Santarpia M; Silvestris N; Spina E
    Front Oncol; 2022; 12():1005626. PubMed ID: 36505840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database.
    Barbieri MA; Sorbara EE; Cicala G; Santoro V; Cutroneo PM; Franchina T; Spina E
    Drugs Real World Outcomes; 2022 Mar; 9(1):91-107. PubMed ID: 34528216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
    Sisi M; Fusaroli M; De Giglio A; Facchinetti F; Ardizzoni A; Raschi E; Gelsomino F
    Target Oncol; 2022 Jan; 17(1):43-51. PubMed ID: 35025076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database.
    Barbieri MA; Sorbara EE; Battaglia A; Cicala G; Rizzo V; Spina E; Cutroneo PM
    Front Pharmacol; 2022; 13():808370. PubMed ID: 35281926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database.
    Zhou Z; Wang C; Ying L; Jin M; Zhang F; Shi D
    J Clin Pharm Ther; 2021 Aug; 46(4):1148-1154. PubMed ID: 33768534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database.
    Magro L; Arzenton E; Leone R; Stano MG; Vezzaro M; Rudolph A; Castagna I; Moretti U
    Front Pharmacol; 2020; 11():622862. PubMed ID: 33536925
    [No Abstract]   [Full Text] [Related]  

  • 9. Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database.
    Barbieri MA; Cutroneo PM; Baratelli C; Cicala G; Battaglia A; Santoro V; Andò G; Spina E
    J Clin Pharm Ther; 2021 Aug; 46(4):1027-1040. PubMed ID: 33646603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous reporting of adverse reactions related to proton pump inhibitors.
    Dipasquale V; Cicala G; Laganà F; Cutroneo P; Trimarchi G; Spina E; Romano C
    Dig Liver Dis; 2023 May; 55(5):595-600. PubMed ID: 36404233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse reactions related to proton pump inhibitors in pediatric population: an analysis of spontaneous reporting data.
    Dipasquale V; Cicala G; Laganà F; Cutroneo P; Felicetti P; Potenza S; Trimarchi G; Spina E; Romano C
    Expert Opin Drug Saf; 2022 Jan; 21(1):127-132. PubMed ID: 34494498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
    Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
    Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
    Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
    Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.
    Aldea A; García Sánchez-Colomer M; Fernández Quintana E; García Sáiz M
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1329-38. PubMed ID: 22415248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database.
    Cutroneo PM; Isgrò V; Ientile V; Santarpia M; Ferlazzo G; Fontana A; Carrega P; Matarangolo E; Barnaba S; Spina E; Trifirò G
    Br J Clin Pharmacol; 2021 Feb; 87(2):527-541. PubMed ID: 32495965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
    Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
    J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
    Huang J; Meng L; Yang B; Sun S; Luo Z; Chen H
    Sci Rep; 2020 Mar; 10(1):4803. PubMed ID: 32179761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.